Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

309.80USD
22 Nov 2017
Change (% chg)

$0.74 (+0.24%)
Prev Close
$309.06
Open
$308.91
Day's High
$311.11
Day's Low
$307.15
Volume
733,319
Avg. Vol
1,311,114
52-wk High
$348.84
52-wk Low
$244.28

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.72
Market Cap(Mil.): $65,515.55
Shares Outstanding(Mil.): 211.48
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.56 15.47
EPS (TTM): -- -- --
ROI: -- 15.17 11.81
ROE: -- 16.58 15.76

BRIEF-Biogen appoints Jeff Capello as executive vice president and chief financial officer

* Appoints Jeff Capello as executive vice president and chief financial officer

Nov 21 2017

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Nov 17 2017

Bill Gates makes $100 million personal investment to fight Alzheimer's

LONDON, Nov 13 Billionaire Microsoft co-founder Bill Gates is to invest $50 million in the Dementia Discovery Fund, a venture capital fund that brings together industry and government to seek treatments for the brain-wasting disease.

Nov 13 2017

BRIEF-Biogen presents new data from long-term extension of phase 1B study

* Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab

Nov 02 2017

UPDATE 1-Sobi to scale up in North America as Q3 beats expectations

Oct 25 Rare-disease drug maker Swedish Orphan Biovitrum (Sobi) reported on Wednesday a bigger jump than expected in quarterly core profit, raised its profit and sales guidance, and said it planned to boost operations in North America.

Oct 25 2017

US STOCKS-Dow jumps with upbeat 3M, Caterpillar earnings

* Indexes up: Dow 0.7 pct, S&P 500 0.2 pct, Nasdaq 0.2 pct (Adds background in paragraph 8.)

Oct 24 2017

US STOCKS-Dow jumps with upbeat 3M, Caterpillar earnings

* Indexes up: Dow 0.7 pct, S&P 0.2 pct, Nasdaq 0.2 pct (Updates to close)

Oct 24 2017

US STOCKS-Wall St gains on 3M, Caterpillar earnings; Dow jumps

* Indexes up: Dow 0.9 pct, S&P 0.3 pct, Nasdaq 0.4 pct (Updates to late afternoon)

Oct 24 2017

Biogen dives as Spinraza U.S. sales miss estimates

Biogen Inc's shares dived 8 percent on Tuesday after U.S. sales of Spinraza, a potential blockbuster drug it is banking on to offset slowing sales of multiple sclerosis drugs, fell short of Wall Street estimates in the latest quarter.

Oct 24 2017

UPDATE 4-Biogen dives as Spinraza U.S. sales miss estimates

* Shares fall as much as 8.14 pct in early trading (Adds details of payment to Neurimmune related to Aducanumab, updates shares)

Oct 24 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $137.29 -1.05
Pfizer Inc. (PFE.N) $35.43 -0.11
Novartis AG (NOVN.S) CHF83.60 --
Merck & Co., Inc. (MRK.N) $54.37 +0.10
Roche Holding Ltd. (ROG.S) CHF246.90 --
Roche Holding Ltd. (RO.S) CHF248.20 --
Bayer AG (BAYGn.DE) €108.50 --
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €77.54 --
GlaxoSmithKline plc (GSK.L) 1,305.50 +3.00

Earnings vs. Estimates